Implication of PMLIV in Both Intrinsic and Innate Immunity

English version České info

PML/TRIM19, the organizer of nuclear bodies (NBs), has been implicated in the antiviral response to diverse RNA and DNA viruses. Several PML isoforms generated from a single PML gene by alternative splicing, share the same N-terminal region containing the RBCC/tripartite motif but differ in their C-terminal sequences. Recent studies of all the PML isoforms reveal the specific functions of each. The knockout of PML renders mice more sensitive to vesicular stomatitis virus (VSV). Here we report that among PML isoforms (PMLI to PMLVIIb), only PMLIII and PMLIV confer resistance to VSV. Unlike PMLIII, whose anti-VSV activity is IFN-independent, PMLIV can act at two stages: it confers viral resistance directly in an IFN-independent manner and also specifically enhances IFN-β production via a higher activation of IRF3, thus protecting yet uninfected cells from oncoming infection. PMLIV SUMOylation is required for both activities. This demonstrates for the first time that PMLIV is implicated in innate immune response through enhanced IFN-β synthesis. Depletion of IRF3 further demonstrates the dual activity of PMLIV, since it abrogated PMLIV-induced IFN synthesis but not PMLIV-induced inhibition of viral proteins. Mechanistically, PMLIV enhances IFN-β synthesis by regulating the cellular distribution of Pin1 (peptidyl-prolyl cis/trans isomerase), inducing its recruitment to PML NBs where both proteins colocalize. The interaction of SUMOylated PMLIV with endogenous Pin1 and its recruitment within PML NBs prevents the degradation of activated IRF3, and thus potentiates IRF3-dependent production of IFN-β. Whereas the intrinsic antiviral activity of PMLIV is specific to VSV, its effect on IFN-β synthesis is much broader, since it affects a key actor of innate immune pathways. Our results show that, in addition to its intrinsic anti-VSV activity, PMLIV positively regulates IFN-β synthesis in response to different inducers, thus adding PML/TRIM19 to the growing list of TRIM proteins implicated in both intrinsic and innate immunity.

Vyšlo v časopise: Implication of PMLIV in Both Intrinsic and Innate Immunity. PLoS Pathog 10(2): e32767. doi:10.1371/journal.ppat.1003975
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1003975

Souhrn

Zdroje

1. TaniguchiT, OgasawaraK, TakaokaA, TanakaN (2001) IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 19: 623–655.

2. Chelbi-AlixMK, WietzerbinJ (2007) Interferon, a growing cytokine family: 50 years of interferon research. Biochimie 89(6–7): 713–718.

3. SadlerAJ, WilliamsBR (2008) Interferon-inducible antiviral effectors. Nat Rev Immunol 8: 559–568.

4. WeissenhornW, HinzA, GaudinY (2007) Virus membrane fusion. FEBS Lett 581: 2150–2155.

5. AlbertiniAA, RuigrokRW, BlondelD (2011) Rabies virus transcription and replication. Adv Virus Res 79: 1–22.

6. EmersonSU, YuY (1975) Both NS and L proteins are required for in vitro RNA synthesis by vesicular stomatitis virus. J Virol 15: 1348–1356.

7. RubinsteinS, FamillettiPC, PestkaS (1981) Convenient assay for interferons. J Virol 37: 755–758.

8. BalachandranS, RobertsPC, BrownLE, TruongH, PattnaikAK, et al. (2000) Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity 13: 129–141.

9. PavlovicJ, ZurcherT, HallerO, StaeheliP (1990) Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein. J Virol 64: 3370–3375.

10. TakaokaA, HayakawaS, YanaiH, StoiberD, NegishiH, et al. (2003) Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424: 516–523.

11. EspertL, DegolsG, GongoraC, BlondelD, WilliamsBR, et al. (2003) ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomic viruses. J Biol Chem 278: 16151–16158.

12. FensterlV, WetzelJL, RamachandranS, OginoT, StohlmanSA, et al. (2012) Interferon-induced Ifit2/ISG54 protects mice from lethal VSV neuropathogenesis. PLoS Pathog 8: e1002712.

13. Chelbi-AlixMK, QuignonF, PelicanoL, KokenMHM, de TheH (1998) Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. J Virol 72: 1043–1051.

14. BonillaWV, PinschewerDD, KlenermanP, RoussonV, GaboliM, et al. (2002) Effects of promyelocytic leukemia protein on virus-host balance. J Virol 76: 3810–3818.

15. LiuSY, SanchezDJ, AliyariR, LuS, ChengG (2012) Systematic identification of type I and type II interferon-induced antiviral factors. Proc Natl Acad Sci U S A 109: 4239–4244.

16. IshovAM, SotnikovAG, NegorevD, VladimirovaOV, NeffN, et al. (1999) PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol 147: 221–234.

17. GeoffroyMC, Chelbi-AlixMK (2011) Role of promyelocytic leukemia protein in host antiviral defense. J Interferon Cytokine Res 31: 145–158.

18. BernardiR, PapaA, PandolfiPP (2008) Regulation of apoptosis by PML and the PML-NBs. Oncogene 27: 6299–6312.

19. PampinM, SimoninY, BlondelB, PercherancierY, Chelbi-AlixMK (2006) Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense. J Virol 80: 8582–8592.

20. El MchichiB, RegadT, MarouiMA, RodriguezMS, AminevA, et al. (2010) SUMOylation Promotes PML Degradation during Encephalomyocarditis Virus Infection. J Virol 84: 11634–11645.

21. EverettRD, Chelbi-AlixMK (2007) PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89(6–7): 819–830.

22. Krieghoff-HenningE, HofmannTG (2008) Role of nuclear bodies in apoptosis signalling. Biochim Biophys Acta 1783: 2185–2194.

23. MarouiMA, PampinM, Chelbi-AlixMK (2011) Promyelocytic leukemia isoform IV confers resistance to encephalomyocarditis virus via the sequestration of 3D polymerase in nuclear bodies. J Virol 85: 13164–13173.

24. RegadT, SaibA, Lallemand-BreitenbachV, PandolfiPP, de TheH, et al. (2001) PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. Embo J 20: 3495–3505.

25. BlondelD, KheddacheS, LahayeX, DianouxL, Chelbi-AlixMK (2010) Resistance to rabies virus infection conferred by the PMLIV isoform. J Virol 84: 10719–10726.

26. KamitaniT, KitoK, NguyenHP, WadaH, Fukuda-KamitaniT, et al. (1998) Identification of three major sentrinization sites in PML. J Biol Chem 273(41): 26675–26682.

27. Lallemand-BreitenbachV, ZhuJ, PuvionF, KokenM, HonoreN, et al. (2001) Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 193: 1361–1371.

28. JensenK, ShielsC, FreemontPS (2001) PML protein isoforms and the RBCC/TRIM motif. Oncogene 20: 7223–7233.

29. NisoleS, MarouiMA, MascleXH, AubryM, Chelbi-AlixMK (2013) Differential Roles of PML Isoforms. Front Oncol 3: 125.

30. SaitohT, Tun-KyiA, RyoA, YamamotoM, FinnG, et al. (2006) Negative regulation of interferon-regulatory factor 3-dependent innate antiviral response by the prolyl isomerase Pin1. Nat Immunol 7: 598–605.

31. NegreD, MangeotPE, DuisitG, BlanchardS, VidalainPO, et al. (2000) Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther 7: 1613–1623.

32. PattonJT, DavisNL, WertzGW (1984) N protein alone satisfies the requirement for protein synthesis during RNA replication of vesicular stomatitis virus. J Virol 49: 303–309.

33. MarieI, DurbinJE, LevyDE (1998) Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J 17: 6660–6669.

34. HondaK, TaniguchiT (2006) IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 6: 644–658.

35. Giron-MichelJ, WeillD, BaillyG, LegrasS, NardeuxPC, et al. (2002) Direct signal transduction via functional interferon-alphabeta receptors in CD34+ hematopoietic stem cells. Leukemia 16: 1135–1142.

36. RegadT, Chelbi-AlixMK (2001) Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 20: 7274–7286.

37. ReicheltM, WangL, SommerM, PerrinoJ, NourAM, et al. (2011) Entrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against varicella-zoster virus. PLoS Pathog 7: e1001266.

38. McAllisterCS, TothAM, ZhangP, DevauxP, CattaneoR, et al. (2010) Mechanisms of protein kinase PKR-mediated amplification of beta interferon induction by C protein-deficient measles virus. J Virol 84: 380–386.

39. McAllisterCS, SamuelCE (2009) The RNA-activated protein kinase enhances the induction of interferon-beta and apoptosis mediated by cytoplasmic RNA sensors. J Biol Chem 284: 1644–1651.

40. MalathiK, DongB, GaleMJr, SilvermanRH (2007) Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature 448: 816–819.

41. CarthagenaL, BergamaschiA, LunaJM, DavidA, UchilPD, et al. (2009) Human TRIM gene expression in response to interferons. PLoS One 4: e4894.

42. NisoleS, StoyeJP, SaibA (2005) TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 3: 799–808.

43. OzatoK, ShinDM, ChangTH, MorseHC3rd (2008) TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol 8: 849–860.

44. SakumaR, MaelAA, IkedaY (2007) Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells. J Virol 81: 10201–10206.

45. CarthagenaL, PariseMC, RingeardM, Chelbi-AlixMK, HazanU, et al. (2008) Implication of TRIM alpha and TRIMCyp in interferon-induced anti-retroviral restriction activities. Retrovirology 5: 59.

46. StremlauM, OwensCM, PerronMJ, KiesslingM, AutissierP, et al. (2004) The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427: 848–853.

47. PertelT, HausmannS, MorgerD, ZugerS, GuerraJ, et al. (2011) TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472: 361–365.

48. GackMU, ShinYC, JooCH, UranoT, LiangC, et al. (2007) TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446: 916–920.

49. YangK, ShiHX, LiuXY, ShanYF, WeiB, et al. (2009) TRIM21 is essential to sustain IFN regulatory factor 3 activation during antiviral response. J Immunol 182: 3782–3792.

50. VersteegGA, RajsbaumR, Sanchez-AparicioMT, MaestreAM, ValdiviezoJ, et al. (2013) The E3-ligase TRIM family of proteins regulates signaling pathways triggered by innate immune pattern-recognition receptors. Immunity 38: 384–398.

51. UchilPD, HinzA, SiegelS, Coenen-StassA, PertelT, et al. (2012) TRIM protein mediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity. J Virol 87: 257–72.

52. WangZG, RuggeroD, RonchettiS, ZhongS, GaboliM, et al. (1998) PML is essential for multiple apoptotic pathways. Nat Genet 20: 266–272.

53. ZennouV, PetitC, GuetardD, NerhbassU, MontagnierL, et al. (2000) HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101: 173–185.

54. StrahleL, MarqJB, BriniA, HausmannS, KolakofskyD, et al. (2007) Activation of the beta interferon promoter by unnatural Sendai virus infection requires RIG-I and is inhibited by viral C proteins. J Virol 81: 12227–12237.

55. UzeG, Di MarcoS, Mouchel-VielhE, MonneronD, BanduMT, et al. (1994) Domains of interaction between alpha interferon and its receptor components. J Mol Biol 243: 245–257.